Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03288493 · ClinicalTrials.gov registry record · Phase 1
P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
A Phase 1 study, sponsored by Poseida Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
NCT03288493: Clinical Trial Phase 1 study, sponsored by Poseida Therapeutics.
NCT03288493 is a Phase 1 study that was terminated before completion, run by Poseida Therapeutics. The registered enrollment target is 105 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03288493, a Phase 1 study, was terminated before completion, sponsored by Poseida Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
Study Summary
Phase 1 of the study is comprised of an open-label, single ascending dose (SAD), multiple cohort study; a multiple dose cycle administration cohort study; and a combination administration study of P-BCMA-101 autologous T stem cell memory (Tscm) CAR-T cells in patients with relapsed / refractory MM. Followed by a Phase 2, open-label, efficacy and safety study. Rimiducid may be administered as indicated.
Primary Outcome
Incidence and severity of treatment-emergent adverse events
Interventions
- DRUG Rimiducid
- BIOLOGICAL P-BCMA-101 CAR-T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2017-09-20 |
| Est. Completion | 2022-04-27 |
| Phase | Phase 1 |
Why NCT03288493 stopped before completion
NCT03288493 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% higher).
The record links to 0 conditions, and to 2 interventions - of which Rimiducid is the first listed.
NCT03288493 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03288493 about?
NCT03288493 is a clinical study titled "P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)". Phase 1 of the study is comprised of an open-label, single ascending dose (SAD), multiple cohort study; a multiple dose cycle administration cohort study; and a combination administration study of P-BCMA-101 autologous T stem cell memory (Tscm) CAR-T cells in patients with relapsed / refractory MM. ...
What is the current status of trial NCT03288493?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2017-09-20. Estimated completion is 2022-04-27.
What interventions are being tested in trial NCT03288493?
The interventions under investigation include: Rimiducid (DRUG), P-BCMA-101 CAR-T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03288493?
This trial is sponsored by Poseida Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03288493's enrollment target sits among peer trials
105 533rd of 2000 higher than 1,465 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI